Výsledky vyhledávání - Sarit Assouline

Upřesnit hledání
  1. 1
    Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia

    Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia Autor Sarit Assouline, Pierre Laneuville, Carlo Gambacorti‐Passerini

    Vydáno 2006
    Získat plný text Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Oxalic acid excretion after intravenous ascorbic acid administration

    Oxalic acid excretion after intravenous ascorbic acid administration Autor Line Robitaille, Orval Mamer, Wilson H. Miller, Mark Levine, Sarit Assouline, David Melnychuk, Caroline Rousseau, L. John Hoffer

    Vydáno 2009
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

    A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies Autor Laurie H. Sehn, Sarit Assouline, Douglas A. Stewart, Joy Mangel, Randy D. Gascoyne, Gregg Fine, Susan Frances-Lasserre, David Carlile, Michael Crump

    Vydáno 2012
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Phase I clinical trial of i.v. ascorbic acid in advanced malignancy

    Phase I clinical trial of i.v. ascorbic acid in advanced malignancy Autor L. John Hoffer, Mark Levine, Sarit Assouline, David Melnychuk, Sebastian J. Padayatty, Kristopher A. Rosadiuk, Caroline Rousseau, Line Robitaille, Wilson H. Miller

    Vydáno 2008
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia

    Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia Autor Sarit Assouline, Valéria Buccheri, Alain Delmer, Gianluca Gaïdano, Christine McIntyre, Michael Brewster, Olivier Catalani, Florence Hourcade‐Potelleret, Pakeeza Sayyed, Xavier C. Badoux

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Systemic cancer therapy: achievements and challenges that lie ahead

    Systemic cancer therapy: achievements and challenges that lie ahead Autor Michael Palumbo, Petr Kavan, Wilson H. Miller, Lawrence Panasci, Sarit Assouline, Nathalie Johnson, Victor Cohen, François Patenaude, Michaël Pollak, R. Thomas Jagoe, Gerald Batist

    Vydáno 2013
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma

    Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma Autor Miguel Alcaide, Stephen Yu, Kevin Bushell, Daniel Fornika, Julie S. Nielsen, Brad H. Nelson, Koren K. Mann, Sarit Assouline, Nathalie A. Johnson, Ryan D. Morin

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E

    A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E Autor Sarit Assouline, Biljana Culjkovic‐Kraljacic, Julie Bergeron, Stephen Caplan, Eftihia Cocolakis, Caroline Lambert, CK Lau, Hiba Ahmad Zahreddine, Wilson H. Miller, Katherine L. B. Borden

    Vydáno 2014
    Získat plný text Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin

    Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin Autor Sarit Assouline, Biljana Čuljković, Eftihia Cocolakis, Caroline Rousseau, Nathalie Beslu, Abdellatif Amri, Stephen Caplan, Brian Leber, Denis‐Claude Roy, Wilson H. Miller, Katherine L. B. Borden

    Vydáno 2009
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma

    Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma Autor Sarit Assouline, Elizabeth Chang, Bruce D. Cheson, Robert M. Rifkin, Solomon I. Hamburg, Ruben Reyes, A-M Hui, Jie Yu, Neeraj Gupta, Alessandra Di Bacco, Yaping Shou, Peter Martin

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma

    A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma Autor Connie Lee Batlevi, Michael Crump, Charalambos Andreadis, David A. Rizzieri, Sarit Assouline, Susan Fox, Richard H. C. Van Der Jagt, Amanda Copeland, Diane Potvin, Richard C. Chao, Anas Younes

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma

    An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma Autor David Andorsky, Kathryn S. Kolibaba, Sarit Assouline, Andres Forero‐Torres, Vicky Jones, Leonard M. Klein, Dipti Patel‐Donnelly, Mitchell R. Smith, Wei Ye, Wen Shi, Christopher A. Yasenchak, Jeff P. Sharman

    Vydáno 2018
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study

    Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study Autor Lambert Busque, Marc-Étienne Beaudet, Michaël Harnois, Hanane Moussa, Natasha Szuber, Luigina Mollica, Robert Delage, Harold J. Olney, Pierre Laneuville, Ghislain Cournoyer, Inès Chamakhi, Marc Lalancette, Danielle Talbot, Vincent Éthier, P. Desjardins, Sarit Assouline

    Vydáno 2025
    Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma

    Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma Autor David Cunningham, Pier Luigi Zinzani, Sarit Assouline, Krimo Bouabdallah, Dominique Bron, Corinne Haïoun, Luigina Mollica, Marius Giurescu, Igor Gorbatchevsky, Manoel Martins das Neves, Marta M. Lemos, Julia Grunert, Florian Hiemeyer, Barrett H. Childs, Martin Dreyling

    Vydáno 2015
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Phase <scp>IA</scp>/<scp>II</scp>, multicentre, open‐label study of the <scp>CD</scp>40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐<scp>H</scp>odgkin or <scp>H</scp>odgkin lymphoma

    Phase <scp>IA</scp>/<scp>II</scp>, multicentre, open‐label study of the <scp>CD</scp>40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐<scp>H</scp... Autor Michelle A. Fanale, Sarit Assouline, John Kuruvilla, Philippe Solal‐Céligny, Dae Seog Heo, Gregor Verhoef, Paolo Corradini, Jeremy S. Abramson, Fritz Offner, Andreas Engert, Martin J.S. Dyer, D. Carreon, Brett Ewald, Johan Baeck, Anas Younes, Arnold S. Freedman

    Vydáno 2013
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study

    Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial... Autor Michael Wang, Sarit Assouline, Manali Kamdar, Nilanjan Ghosh, Seema Naik, Shazia K. Nakhoda, Julio C. Chávez, Ting Jia, Song Pham, Ling‐Yuh Huw, Jing Jing, Wahib S. Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, Lihua E. Budde

    Vydáno 2023
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data

    Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data Autor Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew McMillan, Muhi̇t Özcan, Violaine Safar, Gilles Salles, Grace Ku, Jamie Hirata, Yi Meng Chang, Lisa Musick, Matthew J. Matasar

    Vydáno 2021
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Autor Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers, Manali Kamdar, Andrew McMillan, Mark Hertzberg, Sarit Assouline, Tae Min Kim, Won Seog Kim, Muhıt Özcan, Jamie Hirata, Elicia Penuel, Joseph N. Paulson, Ji Cheng, Grace Ku, Matthew J. Matasar

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with <scp>G</scp>aucher disease type 1: The phase 3 ENGAGE trial

    Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with <scp>G</scp>aucher disease type 1: The phase 3 ENGAGE trial Autor Pramod K. Mistry, Elena Lukina, Hadhami Ben Turkia, Suma P. Shankar, Hagit Baris, Marwan Ghosn, Atul Mehta, Seymour Packman, Gregory M. Pastores, Мilan Petakov, Sarit Assouline, Manisha Balwani, Sumita Danda, Evgueniy Hadjiev, Andres Ortega, Sebastiaan J.M. Gaemers, Regina Tayag, Michel Peterschmitt

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

    Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas Autor Stephen J. Schuster, Ling‐Yuh Huw, Christopher R. Bolen, Victor Maximov, Andrew G. Polson, Katerina Hatzi, Elisabeth A. Lasater, Sarit Assouline, Nancy L. Bartlett, Lihua E. Budde, Matthew J. Matasar, Hartmut Koeppen, Emily Piccione, Deanna Wilson, Michael C. Wei, Shen Yin, Elicia Penuel

    Vydáno 2023
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: